Neurogene, Inc. (NGNE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$27.58+3.41%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · NGNE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 263.4% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
NGNE — earnings miss
Dated 2026-08-11
Results of Operations and Financial Condition On August 11, 2026, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on August 11, 2026, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.…
Why it matters: The company reported about $360.2 million in pro forma cash. A shorter runway could add funding pressure before the trial readout.
Worry ifA later company update still says current cash can fund planned work through Q1 2029 or later.
Less concerning ifA later company update moves the cash runway to before Q1 2029 or reports a need for new funding sooner.
Why it matters: Embolden’s main test is whether enough people improve. The result will test the Phase 1/2 findings in the larger trial.
Watch forTopline data in 2H 2027 show at least 8 of the first 24 participants meet the response endpoint.
Also watch forTopline data show fewer than 8 of the first 24 participants meet the response endpoint.
Why it matters: R&D spending and net loss rose year over year in Q2 as NGN-401 work grew. A further rise could increase pressure on the cash runway.
Worry ifThe November 12, 2026 results show quarterly R&D above $25.5 million or net loss above $34.5 million.
Less concerning ifThe November 12, 2026 results show quarterly R&D at or below $25.5 million and net loss at or below $34.5 million.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$287 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $773 loss on $10,000 · 7.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,967 loss on $10,000 · 49.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.